NATALIE LEN: Open Payments
NPI 1013629047 · OLDSMAR, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,481 in 213 payments from 22 companies in 2025. Trend: 2023 $5,864 · 2024 $4,344 · 2025 $4,481
Food & beverage: $4,474Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $757 |
| Otsuka America Pharmaceutical, Inc. | 19 | $532 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $453 |
| Lundbeck LLC | 12 | $284 |
| Noven Therapeutics, LLC | 19 | $262 |
| Neurocrine BioSciences, Inc. | 16 | $248 |
| Neuronetics, Inc. | 3 | $246 |
| Supernus Pharmaceuticals, Inc. | 21 | $245 |
| Alkermes, Inc. | 9 | $219 |
| Corium, LLC | 11 | $195 |
Products named: REXULTI, VRAYLAR, CAPLYTA, Xelstrym, INGREZZA, NEUROSTAR TMS THERAPY SYSTEM, Qelbree, Azstarys.
Industry payments across FL — which companies pay providers there.
